Anixa Biosciences (ANIX) announced that final results from the Phase 1 clinical trial of its breast cancer vaccine will be presented at the 2025 San Antonio Breast Cancer Symposium, SABCS, on Thursday, December 11, 2025. The trial, conducted at Cleveland Clinic and funded by a grant from the U.S. Department of Defense, evaluated the safety and immunogenicity of an alpha-lactalbumin vaccine for breast cancer. The presentation, titled “Final Results of a Phase I Trial of alpha-lactalbumin Vaccine for Breast Cancer,” will be delivered by Justin Johnson, Ph.D., Program Manager at Cleveland Clinic and co-inventor of the vaccine technology.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa Biosciences: Promising Clinical Progress and Financial Stability Underpin Buy Rating
- Anixa Biosciences files $200M mixed securities shelf
- Promising Advancements and Strategic Positioning Propel Anixa Biosciences to a Buy Rating
- Anixa completes dosing of fourth cohort in Phase 1 trial of CAR-T/CER-T therapy
- Anixa receives notice of allowance in China for cancer vaccine technology patent